• 1
    World Health Organization (WHO), International Society of Hypertension (ISH) Writing Group. 2003 WHO/ISH statement on management of hypertension. J Hypertens. 2003;21:19831992.
  • 2
    Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet. 2003;362: 15271535.
  • 3
    The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens. 2007;25:11051187.
  • 4
    Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Eng J Med. 2003;348:583592.
  • 5
    Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 6
    Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendoflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895906.
  • 7
    Kjeldsen SE, Stålhammar J, Hasvold P, et al. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Human Hypertens. 2009;24:263273.
  • 8
    World Health Organization. WHO report on the global tobacco epidemic, 2009. Accessed October 02, 2010.
  • 9
    Profdoc Software. 2008. Accessed October 02, 2010.
  • 10
    Lidman B, Linder R Working Model 2007. Accessed October 02, 2010.
  • 11
    Sekhon , Jasjeet S forthcoming. “Multivariate and Propensity Score Matching Software with Automated Balance Optimization. Journal of Statistical Software. .
  • 12
    Konstam MA, Neaton JD, Dickstein K, et al. for the HEAAL investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:18401848.
  • 13
    Henriksson M, Russell D, Bodegard J, et al. Health-care costs of losartan and candesartan in the primary treatment of hypertension. J Hum Hypertension: 2010; doi: 10.1038/jhh.2010.36.
  • 14
    Young JB, Dunlap ME, Pfeffer MA, et al; for the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) investigators and committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low left-ventricular ejection fraction trials Circulation. 2004;110:26182626.
  • 15
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study, ELITE II. Lancet. 2000;355:15821587.
  • 16
    Ojima M, Inada Y, Shibouta Y, et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1-receptor. Eur J Pharmacol. 1997;319:137146.
  • 17
    Morsing P, Vauquelin G. How can the differences among AT1-receptor antagonists be explained? Cell Biochem Biophys. 2001;35:89102.
  • 18
    Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Am J Hypertens. 1999;12:11811187.
  • 19
    Bakris G, Gradman A, Reif M, et al. for the CLAIM Study investigators. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens. 2001;3:1621.
  • 20
    Vidt DG, White WB, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens. 2001;15:475480.
  • 21
    Okin PM, Devereux RB, Hille DA, et al. Concomitant hydrochlorothiazide therapy in hypertensive patients is associated with reduced cardiovascular morbidity and mortality independent of blood pressure and electrocardiographic left ventricular hypertrophy: the LIFE study. Circulation. 2008;118:886.
  • 22
    Okin PM, Hille DA, Kjeldsen SE, et al. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients. Am J Hypertens. 2010; doi: 10.1038/ajh.2010.65.